Introduction
Erythropoiesis, the orderly continuous process by which committed erythroid progenitor cells differentiate into mature circulating erythrocytes, requires (1) a normal hematopoietic progenitor cell pool, (2) an adequate supply of essential nutrients such as iron, folic acid, and vitamin B12, and (3) ongoing exposure to specific hematopoietic growth factors. While the major function of the red cell is to transport oxygen from the lungs to the other tissues, the coupling of long-term tissue oxygen requirements with long-term blood oxygen carrying capacity is the function of the hematopoietic growth factor erythropoietin.
Endogenous Erythropoietin Production
Among the hematopoietic growth factors, erythropoietin is one of few that behaves like a hormone. It is unique because its production, under normal circumstances, is controlled solely at the level of its gene by tissue hypoxia and not by the absolute number of circulating erythrocytes. Although a variety of growth factors influence erythroid progenitor cell proliferation, erythropoietin is the most important, and erythropoiesis cannot continue in its absence.
Erythropoietin is a 30,400 m.w. glycoprotein that is produced primarily in the kidneys in adults and, to a lesser extent, in the liver. In the kidneys, erythropoietin is produced in fibroblastoid interstitial cells in the inner renal cortex, 1 while in the liver, the hormone is produced by both hepatocytes and interstitial fibroblastoid cells. 2 It is also produced in other tissues such as the testes and brain in an amount that is negligible in comparison with its production in the kidneys and liver. Moreover, its function in the testes and brain is unknown. 3 Hypoxia is the sole physiologic stimulus for erythropoietin production. However, transient elevations of serum erythropoietin occur initially with the use of chemotherapeutic drugs 4 and zidovudine 5 and have also been observed with hepatocellular damage. 6 More persistent elevation of serum erythropoietin can occur with certain tumors, primarily those arising in the kidneys, liver, and cerebellum. 7 In the kidney, erythropoietin production occurs on an all-or-none basis in each cell; normally, there is constitutive production of the hormone that is commensurate with its role as a survival factor as well as a mitogen. 8, 9 With increasing tissue hypoxia, more renal tubular interstitial cells are recruited to produce erythropoietin. 10 Erythropoietin production in the liver is also constitutive, but in contrast to the kidneys, it can be modulated in each hepatocyte depending on the degree of tissue oxygenation. The behavior of hepatic fibroblastoid cells with respect to erythropoietin production is still undefined. 3 Furthermore, the threshold for up-regulation of erythropoietin production is much higher in the liver than in the kidneys. Even though the liver is a larger organ, in the absence of the kidneys, liver erythropoietin production is unable to maintain an adequate hemoglobin level.
Erythropoietin Interactions With Erythroid Progenitor Cells
Following production in the kidneys and liver, erythropoietin travels to the bone marrow to interact with specific hematopoietic progenitor cells. Specificity is provided by the surface of expression of high-affinity receptors for the hormone, 11 and these receptors are primarily expressed on erythroid progenitor cells. The earliest committed erythroid progenitor cell is called the BFU-E (burst-forming unit -erythroid) because of the large size of the colonies it forms in vitro. BFU-Es are characterized by a high proliferative potential, a requirement for other hematopoietic growth factors, such as IL-3 and stem cell factor, and a low number of erythropoietin receptors. BFU-Es are largely dormant. 12 Because BFU-Es have a low number of erythropoietin receptors, they require a high concentration of erythropoietin to enter the cell cycle (Table 1) . For these cells, therefore, erythropoietin acts as a mitogen, and its production must be inducible to reach a level sufficient to trigger these cells into cycle ( Table 2) .
As they mature, BFU-Es gradually lose their proliferative capacity and acquire more erythropoietin receptors. At this stage, the cells are called CFU-E (colony- forming unit -erythroid). CFU-Es have a reduced capacity for proliferation, form small colonies in vitro, and are largely in cell cycle. Therefore, CFU-Es require erythropoietin not to proliferate but rather to maintain their viability as they differentiate (Table 1) . 8 It is for this reason that erythropoietin production is constitutive.
Studies of erythroid progenitor cells overexpressing specific survival genes indicate that these cells can differentiate in the absence of erythropoietin. This suggests that the role of erythropoietin in maturing erythroid progenitor cells with respect to differentiation is permissive (as a survival factor) and not instructive. 13 (Table 2) . Erythropoietin receptors have been identified in a variety of other cell types such as endothelial cells 14 and neural cells, 15 but the role of erythropoietin in the physiology of these cells is unknown.
Regulation of Erythropoietin Production
As mentioned, erythropoietin behaves like a hormone. Tissue hypoxia stimulates its production, and an excess of oxygen suppresses its production but never completely. Therefore, if a reliable assay for circulating erythropoietin were available, it would be possible to assess tissue hypoxia. Fortunately, the immunoassay for serum erythropoietin using recombinant erythropoietin-derived reagents has proved useful for this purpose. This is due to several factors: (1) there is only one form of circulating erythropoietin, (2) there are no preformed stores of erythropoietin, 16 (3) immunologically detectable erythropoietin is equivalent to biologically active erythropoietin, 17 (4) erythropoietin production is regulated at the level of its gene, (5) hypoxia is the only physiologic stimulus for erythropoietin production, (6) erythropoietin production is not influenced by its plasma level 18 or marrow cellularity, 19 (7) erythropoiesis metabolism is not influenced by its plasma level, 20 (8) neither age nor gender influences the plasma erythropoietin level, 21 and (9) plasma erythropoietin is constant in a given individual. 22 Given the strong inverse correlation between erythropoietin production and tissue hypoxia or anemia, there should be an inverse correlation between plasma erythropoietin and the hemoglobin or hematocrit level. While this is true in situations such as chronic iron deficiency anemia or chronic hemolytic anemia, it is not the case in other situations due to a strong central tendency for down-regulation of erythropoietin production under normal circumstances and with certain diseases (Table  3 ). For example, normal men and women differ with respect to red cell mass (and hemoglobin or hematocrit), but they do not differ with respect to their plasma erythropoietin level (Table 4) . Reduction in testosterone production, however, causes equalization of the hemoglobin level between men and women. 23 Thus, within the normal range of hemoglobin or hematocrit, factors other than erythropoietin are involved in the regulation of erythropoiesis. Furthermore, until the hemoglobin level falls below 10.5 g/dL, the plasma erythropoietin level does not rise outside the normal range. 22 This is not to say that small reductions in hemoglobin will not cause an increase in erythropoietin production. Rather, the increase is modest and, given the wide range of normal for plasma erythropoietin (4 to 26 mU/mL), a more significant hemoglobin reduction is required to raise erythropoietin production to the extent that plasma erythropoietin increases beyond normal range. This has important clinical implications since it suggests that a substantial degree of anemia or tissue hypoxia must occur before a significant increase in erythropoietin production occurs. For this reason, the amount of blood that can be donated at any one time or over a short duration is limited, since the increase in erythropoietin production caused by phlebotomy is not marked.
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Impairment of Erythropoietin Production
In addition to the normal central tendency for down-regulation of erythropoietin production, a number of disease states impact negatively on erythropoietin production (Table 3) . Because erythropoietin is produced primarily in the kidneys, its production and therefore its plasma level are sensitive to impairment of renal function. Thus, once the serum creatinine rises outside the normal range, the expected correlation between plasma erythropoietin and the hemoglobin level is lost. 22 Hyperviscosity also impairs erythropoietin production by an unknown mechanism. 25, 26 This probably serves as a protective mechanism against exacerbation of hyperviscosity by a rising red cell mass in situations such as hypoxic erythrocytosis or a plasma protein dyscrasia.
Most disease-related causes of impaired erythropoietin production (Table 3) probably occur by a common mechanism involving the production of inflammatory cytokines that not only suppress the production of erythropoietin but also interfere with the proliferation of erythroid progenitor cells. 27 Thus, patients with chronic inflammatory or infectious disorders or neoplasia, while capable of increasing their erythropoietin production, produce less erythropoietin for any degree of anemia than do patients with uncomplicated iron deficiency anemia or chronic hemolytic anemia. 5, 28, 29 Furthermore, the quantity of erythropoietin produced is also insufficient to overcome the suppressive effects of inflammatory cytokines on the proliferative response of erythroid progenitor cells to erythropoietin. In addition to the disorders that impair erythropoietin production, an inappropriate increase in erythropoietin production is caused by a number of conditions, including liver disease or the use of zidovudine and chemotherapeutic agents. [4] [5] [6] With respect to liver disease, the increase in erythropoietin production may represent hepatocyte regeneration with a recapitulation of ontogeny when the liver is the primary site of erythropoietin production. The mechanism by which certain drugs cause elevation of plasma erythropoietin remains unknown. Measurement of the plasma erythropoietin level can provide a useful gauge of erythropoietin production if the guidelines listed in Table 5 are followed. Generally, a low level of plasma erythropoietin in an anemic patient suggests a hormone-deficient state that can be corrected with recombinant erythropoietin therapy if the bone marrow is responsive. In an anemic patient, a high level of plasma erythropoietin (particularly over 1000 mU/mL) in the absence of zidovudine, liver disease, or chemotherapeutic agents suggests a bone marrow that is unable to respond to the hormone. Before considering the use of recombinant erythropoietin, it is important to exclude correctable causes of anemia such as nutritional deficiency states or lesions that cause bleeding, as well as underlying conditions that predispose to anemia (ie, hypothyroidism). 
